Nanobacteria Implicated in Most All Degenerative Diseases

Major Breakthrough in ArterialAudios | Contact Site | Hands | Health | Letters Library | Missions | News | Sermons Short Stories | Sunset Calendar | Toolbox | Vatican Watch | Videosis an excerpt from the June '02 issue of The SinatraAudios | Contact Site | Hands | Health | Letters Library | Missions | News | Sermons Short Stories | Sunset Calendar | Toolbox | Vatican Watch | VideosReport, the monthly newsletter of Stephen Sinatra MD FACC, which is reproduced with the permission of Dr. Sinatra and Phillips Health LLC. If you are interested in N. sanguineum, Nanobiotic therapy, and EECP, then you will probably be interested in what Dr. Sinatra has to say about cardiovascular disease and the treatments available to you - I read Dr. Sinatra's newsletter and so do my patients. To learn more about Dr. Sinatra and/or to subscribe to The SinatraAudios | Contact Site | Hands | Health | Letters Library | Missions | News | Sermons Short Stories | Sunset Calendar | Toolbox | Vatican Watch | VideosReport go to http://www.drsinatra.com/ or call Phillips Health LLC at (800) 211-7643.

Nanobacteria: Major Breakthrough in ArterialAudios | Contact Site | Hands | Health | Letters Library | Missions | News | Sermons Short Stories | Sunset Calendar | Toolbox | Vatican Watch | Videos

By Stephen Sinatra, MD, FACC, FACN

Like every cardiologist on the planet, I used to think oxidized LDL cholesterol created the plaque that caused atherosclerosis (hardening of the arteries). Trouble was, there were many cases of cardiovascular disease that this theory couldn’t account for. Oxidized LDL may be part of the story, but it’s not the full explanation. The exciting news is that nanobacteria may well be.

Nanobacteria, formally known as Nanobacterium sanguineum, are so minute that they eluded researchers for decades. They’re 1/1,000 the size of normal bacteria, and until recently, nobody believed that something so small could even be alive. It turns out that nanobacteria are not only very much alive but thriving, and they are damaging our health in more ways than we could have ever dreamed.

As you know, a mission of mine has been to try to explain how and why heart disease occurs in people who don’t exhibit the traditional risk factors. If we can hit upon the cause, then we can help prevent thousands of unexplained deaths each year. There have been numerous hypotheses, but so many never pan out. Take Chlamydia pneumoniae, the pathogen that causes acute respiratory disease, for example. Remember the news reports from just a few years ago that proclaimed infection with this bacterium probably accounted for much of the unexplained plaque in people? The hope was that we could treat the C. pneumoniae and thereby eradicate the plaque. Well, further research uncovered C. pneumoniae in only a small percentage of all plaque—certainly not enough to be a pervasive cause. I never jumped on the chlamydia bandwagon because the research was not convincing and was too often contradictory.

When I first heard about nanobacteria, I was skeptical, too. But I have looked into the subject at length and talked with physicians involved, and now I’m convinced that the study of nanobacteria will bring about a whole new understanding of a number of diseases. This kind of understanding is what leads to treatments and eventually cures.

The Nanobac Story in Brief

In 1988 Olavi Kajander, M.D., Ph.D., and Neva Ciftcioglu, Ph.D., were conducting research on mammalian cells at the University of Kuopio in Finland, work that is ongoing today. As so often happens in basic medical research, the cells in their cell cultures kept dying. But, instead of just throwing them out, as researchers usually do, the two scientists forgot about the dead cell cultures in the incubator. Months later, they retrieved these cultures and started to investigate an unusual, hardened film that had formed on the culture surfaces. What they discovered were tiny bacteria—20–200 nanometers in size—in calcified shells.

The discovery of nanobacteria should have been a major moment in bacterial research history, yet no journal would publish their findings! The bacteria were so small that no one could believe they were alive. It was not until 1997 that their findings were finally published in a medical journal. (This is a good example of how slowly the medical establishment moves.)

In their research, Kajander and Ciftcioglu—who have been nominated for a Nobel prize—found that nanobacteria were social little creatures, banding together to secrete an irritating toxic film that causes swelling and inflammation. The film provides them with protection so they can connect and colonize like slime molds, expanding, contracting, and moving. Eventually, this film hardens into a shell, protecting the nanobacteria colony from our body’s attempts to clear it out.

Even in this calcified state, nanobacteria aren’t necessarily dormant; they can continue to aggregate and reproduce. And our body doesn’t recognize them as a foreign pathogen at this stage. They’re just seen as calcium, so the nanobacteria are free to expand unchecked. (To see one in the middle of cellular division, and other photos, visit www.nanobaclabs.com)

Nanobacteria are a bit sluggish at the multiplication game. Unlike most bacteria, which replicate in minutes or hours, nanobacteria take about three days to reproduce, which helps explain why their significance may have been underestimated for so long. This slow replication means that nanobacteria may be in the body as long as 40 years before symptoms like inflammation and noticeable plaque develop.

The biofilm phase of nanobacterial life is one of the most damaging to human bodies, because the biofilm is a potent toxin that causes the body to react powerfully with irritation and swelling. Though the “bugs” themselves cause damage, even more damage is caused by the body’s reaction to them. In other words, the body, in trying to react to the damage, hurts itself. The body’s defenses in turn trigger several medical markers of inflammation, including the well-known C-reactive protein (CRP), which helps explain why elevated CRP levels are a major harbinger of coronary artery disease.

An Apt Analogy

To help illuminate what the discovery of nanobacteria could ultimately mean for our health, let’s take a look at H. pylori and ulcers. It was only after years of having patients undergo gastric surgery that doctors learned a bacterium known as Helicobacter pylori was the culprit in many ulcers. So surgeons were putting patients with ulcers through major surgery, cutting their vagus nerve (the extensive cranial nerve that extends to the abdomen) and revamping part of their small intestine, when treatment turned out to be easily achieved with antibiotics in most cases.

In the same way, interventional cardiologists are going in and cutting the blood vessels around patients’ hearts to bypass plaque-filled arteries in what has become an alarmingly common procedure. We may learn that all that’s needed for severely calcified arteries is a course of the right antibiotic. (Actually, nanobacteria treatment is more complicated, but I’ll get to that in a moment.)

Scientists from the Hungarian Academy of Sciences have reported finding nanobacteria in more than 60 percent of human artery-clogging plaques studied. The Hungarians also confirmed and validated previous research reports of how truly miniscule these bacteria are and therefore how easily they can enter the body via blood exchange and blood products. With their protective apatite coat, nanobacteria are highly resistant to heat, radiation, and all antibiotics—except tetracycline.

Eradicating N. sanguineum

NanobacLabs, based in Tampa, FL, has been conducting research with a special therapy that has been instrumental in nanobacterium killing and along with that, plaque reversal. Nanobac-
Labs researchers have performed a pilot study of 91 patients using the following protocol on a daily basis over several months:

• 500 mg oral tetracycline

• 1,500 mg EDTA rectal suppository (EDTA is a weak synthetic amino acid that works as a chelating agent to gradually infiltrate mineral deposits and pull them away from the cardiovascular system.)

• a mixture of compounds taken by mouth that retards the excretion of EDTA

The premise is as follows: Tetracycline is the only antibiotic known to kill nanobacteria, but it needs a way to infiltrate their calcified shells. Enter EDTA chelation, which is used to “fluff up” the plaque, allowing tetracycline access to the bacteria. The added oral powder keeps the EDTA in your bloodstream longer so the tetracycline has more time to eradicate the bacteria.

Of the 91 participating patients, the mean decrease in their coronary artery calcification scores was 58.5 percent after treatment with NanobacTX therapy for three months. Interestingly, in 19 of those 91 patients 100 percent of coronary artery calcification was eradicated. These are truly amazing statistics! I know of no other treatment that is so successful. NanobacLabs is now conducting a much larger study of plaque reversal, and some of my patients are participating.

A minimum of four months of NanobacTX treatment is necessary to treat many folks with coronary artery calcification. For those whose plaque burden is excessive, nine to twelve months (or more) of therapy may be needed. From the cardiologists reporting back so far, most patients start seeing a marked improvement in quality of life in four to six weeks. It is also interesting to note that many patients have reported the resolution of co-existing illnesses. (See “Diseases Associated with Calcified Plaque,” page 5.)

Not a Cure-All

Despite all the promising early news about NanobacTX, it should not be considered a panacea. First, it needs to be tested in larger clinical trials of longer duration before I’m confident of its usefulness. Second, “fluffing” the calcified plaque to allow the tetracycline ample penetration could possibly precipitate angina. Such was the case for one of my patients, who had to withdraw from the study.

For now, I would refer those patients with very high calcium scores or those with angina who have a poor quality of life and are running out of options. This is where the real beauty of nanobacteria treatment lies—providing one more card for us physicians to play when the stakes are the highest. Otherwise, there’s so little we can do when someone’s vessels are clogged beyond repair.

Perhaps we’ll eventually discover new combinations of procedures. James Roberts, MD, FACC, of Toledo, Ohio, reports using NanobacTX as a stepping-stone to EECP. (Enhanced External Counter Pulsation is a therapy to help the body naturally bypass blocked arteries. See SHR February 2001 or Dr. Roberts’s Web site, www.heartfixer.com, for more information.)

What You Can Do Now

The bottom line is that coronary artery disease (as well as many other diseases) is a process of inflammation. This inflammation can be caused by nanobacteria and then compounded by traditional risk factors, or it may be the result of any combination of excess oxidized LDL, lipid peroxides from saturated fats, cigarette smoking, heavy metal toxicities, a sedentary lifestyle, and so on. It’s still difficult to say in individual cases what the root cause might be. The science is just not there yet.

There are a few blood tests to screen for nanobacteria, but none are conclusive. (If you’re in a high-risk group and want more information about screening now, ask your physician or contact NanobacLabs directly: 10330 North Dale Mabry Highway, Suite 226, Tampa, FL 33618; phone 813-264-2241. Ask about their NanobacTest.)

Finally, to gain a better understanding of inflammatory heart disease, I highly recommend an article in the May 2002 issue of Scientific American, “Atherosclerosis–the New View” by Dr. Peter Libby. Although there’s no discussion of nanobacterium, and the article is somewhat technical, it’s appropriate for the general reader, especially my savvy subscribers. I could spend an entire newsletter on this topic, but not every reader would be thrilled.
So please read Dr. Libby’s article if you’re intrigued.

I hope you’re as excited as I am about this breakthrough research. Even as I write this, additional scientific commentary is coming in. This could be the biggest medical science story of the 21st century. Rest assured that I’ll continue to track the nanobacteria story and share it with you as it evolves.

References

Ciftcioglu N, et al. Nanobacteria: an infectious cause of kidney stone formation. Kidney International. 1999;56:1893-1898.

Kajander O, et al. Nanobacteria from blood, the smallest culturable autonomously replicating agent on Earth. Proc SPIE. 1997;3111:420-28.

Kajander O, et al. Nanobacteria: an alternative mechanism for pathogenic intra- and extra-cellular calcification and stone formation. Proc Natl Acad Sci 1998;95:8274-8279.

Libby P. Atherosclerosis: the new view. Scientific American. May 2002: 24-55.

Used with permission of Phillips Health, LLC. To subscribe to The Sinatra Health Report by Dr. Stephen Sinatra, or for more information about the topics Dr. Sinatra covers in his newsletter, please call (800) 211-7643.


Nanobacteria has been implicated in:

Atherosclerotic Plaque
Blood Disorders
Breast Calcification
[certain] Cancers
Cataracts
Coronary Artery Plaque
Dental Plague
Eczema
Fibromyalgia
Heart Disease
Kidney Stones
Lichen Planus
Liver Cysts
Myelodegenerative disorders such as Multiple Sclerosis, Lou Gehrig’s Disease & Alzheimer’s Disease
Osteoarthritis
Polycystic Kidney Disease
Psoriasis
Periodental Disease
Prostate Calcification
Rheumatoid Arthritis
Sclerdoma

Nanobacteria and its pathological calcification are implicated to be either the cause or instrumental in most ALL degenerative disease processes.